Bayer Aktiengesellschaft (BAYN.DE) Stock
Bayer Aktiengesellschaft

Company profile
Bayer Aktiengesellschaft reported revenue of 45.58 billion EUR for fiscal year 2025, down 2.2% from fiscal year 2024. In Q3 2026 (the quarter ended September 30, 2026) revenue was 10.05 billion EUR, up 4.1% from a year before. Its largest business segment, Crop Science, brought in 48% of segment revenue in fiscal year 2025; United States was the largest region with 33%. In Q3 2026 it reported a net loss of 672.00 million EUR, against a net loss of 963.00 million EUR a year earlier. Our analysis of its filings shows revenue shrinking from 47.64 billion EUR in fiscal year 2023 to 45.58 billion EUR in fiscal year 2025, 2.2% a year on average. Bayer Aktiengesellschaft reports about 87,775 full-time employees.
What stands out
- It reported a net loss in each of its last 3 fiscal years, after a profit of 4.15 billion EUR in fiscal year 2022; the loss widened from 2.55 billion EUR in fiscal year 2024 to 3.62 billion EUR in fiscal year 2025.
- It was founded in 1863.
Figures from company filings; latest fiscal year ended December 31, 2025.
About Bayer Aktiengesellschaft
Bayer Aktiengesellschaft operates as a life science company in Europe, the Middle East, Africa, Germany, Switzerland, North America, the United States, the Asia Pacific, China, Latin America, and Brazil. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment provides prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy. The Consumer Health segment offers nonprescription over-the-counter medicines for self-medication and self-care; nutritional supplements; allergy, cough, and cold; dermatology; pain and cardiovascular risk prevention; and digestive health products. The Crop Science segment offers chemical and biological crop protection products, improved plant traits, seeds, digital solutions, and pest and weed management products, as well as customer services for agriculture. It also engages in the breeding, propagation, and production/processing of seeds, including seed dressing. The company distributes its products through wholesalers, pharmacies and pharmacy chains, supermarkets, online and other retailers, and hospitals, as well as directly to farmers. Bayer Aktiengesellschaft has a strategic alliance with The University of Colorado Anschutz, along with UCHealth and Children's Hospital Colorado to advance drug development and clinical trials. Bayer Aktiengesellschaft has a strategic alliance Henry Ford Health. It has a commercial agreement with Neste to Jointly scale newgold winter canola for biofuels production. Bayer Aktiengesellschaft was founded in 1863 and is based in Leverkusen, Germany.
Largest shareholders
- Amundi Asset Management SAS (Investment Management)3.04%
- Silchester International Investors LLP2.99%
- Harris Associates LP2.98%
- Temasek Holdings Pte Ltd. (Investment Management)2.90%
- Dodge & Cox2.87%
Share of the company, as of September 25, 2026
Leadership
- William N. Anderson — Chairman of the Management Board & CEO, 59
- Stefan Oelrich — President of the Pharmaceuticals Division & Member of the Board of Management, 57
- Rodrigo Santos — Member of Management Board, Head of the Crop Science Division & President of Crop Science Division, 52
- Julio Triana — Member of Management Board & President of Consumer Health Division, 60
- Judith Hartmann — CFO & Member of Management Board, 56
How much revenue does Bayer Aktiengesellschaft make?
Bayer Aktiengesellschaft reported 45.58 billion EUR in revenue for fiscal year 2025, down 2.2% from 46.61 billion EUR in fiscal year 2024. In Q3 2026 revenue was 10.05 billion EUR.
What is Bayer Aktiengesellschaft's largest business segment?
Crop Science, with 21.68 billion EUR or 48% of segment revenue in fiscal year 2025. Next: Pharmaceuticals (39%) and Consumer Health (13%).
Where does Bayer Aktiengesellschaft make most of its revenue?
United States: 33% of revenue by region in fiscal year 2025, followed by Europe / Middle East / Africa (23%).
What companies are similar to Bayer Aktiengesellschaft?
Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Merck KGaA (MRK.DE), Dermapharm Holding SE (DMP.DE), Biotest Aktiengesellschaft (BIO3.DE), Cannovum Cannabis AG (27N0.DE).
Has Bayer Aktiengesellschaft made a profit in recent years?
Net income by fiscal year: FY2021, 1.00 billion EUR; FY2022, 4.15 billion EUR; FY2023, a loss of 2.94 billion EUR; FY2024, a loss of 2.55 billion EUR; FY2025, a loss of 3.62 billion EUR. It reported a net loss in 3 of these 5 years.
Company Information
Contact & Links
Data as of .
How to cite: DataPorium, “Bayer Aktiengesellschaft (BAYN.DE)”, data as of Sep 30, 2026, https://dataporium.tech/stocks/BAYN.DE